Detailed Narrative
Q1 FY26 Financial Performance Overview
Dr. Reddy's reported consolidated revenues of ₹8,545 crores ($997 million) for Q1 FY26, marking an 11% year-on-year growth but remaining flat sequentially. The EBITDA margin stood at 26.7%, slightly exceeding the company's aspiration of 25%, despite a 149 basis points year-on-year and 243 basis points quarter-on-quarter decline. This margin compression was primarily attributed to a 350 basis points YoY decrease in gross profit margin, driven by price erosion in generics, particularly Lenalidomide, and lower operating leverage. Profit after tax attributable to equity holders grew 2% YoY to ₹1,419 crores ($166 million).
Segmental Business Performance
The US generics business faced headwinds, declining 17% YoY to $400 million, mainly due to price erosion in Lenalidomide and timing of📎 procurement. In contrast, European generics revenues surged 124% YoY to €131 million, boosted by contributions from the acquired Nicotine Replacement Therapy (NRT) portfolio and new product launches. Emerging Markets grew 10% YoY to ₹1,404 crores, with Russia contributing a 17% YoY increase. The India business also delivered robust growth of 11% YoY to ₹1,471 crores, outperforming the Indian Pharmaceutical Market.
Strategic Investments and Pipeline Progress
The company continues to make targeted R&D investments, which were ₹624 crores (7.3% of sales) this quarter, focusing on complex generics, API, and biosimilars. Key pipeline assets like Semaglutide and Abatacept are progressing, with Semaglutide's Canadian launch targeted for January 2026 and Abatacept's Phase III readout expected in November 2025. The biosimilars portfolio was strengthened by a strategic collaboration with Alvotech for the co-development, manufacture, and commercialization of pembrolizumab. The CDMO business is projected to achieve $100 million in sales for FY26 and $250-300 million by 2030.
Regulatory and Operational Updates
During the quarter, the USFDA inspected the Middleburgh API facility and Miryalaguda API facility, both receiving two Form 483 observations, which have since been addressed or are being responded to. More recently, the FTO-11 formulations facility in Srikakulam received seven Form 483 observations, for which the company expects a VAI classification. The phased integration of the acquired NRT business is proceeding as planned, with additional markets like Canada, Australia, and Western Europe being onboarded.
Capital Allocation and Outlook
Dr. Reddy's reported a net cash surplus of ₹2,922 crores ($341 million) and a Capex cash outflow of ₹683 crores ($80 million) for the quarter. The full-year Capex is projected to be between ₹2,500-₹2,700 crores, with significant allocation to peptides and biosimilars. Management aims to maintain SG&A at 28-29% of sales for the full year, down from 30% in Q1, and expects a normalized effective tax rate of around 25%. The company also indicated a maximum net debt to EBITDA ratio of 0.5.